Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19
Hospitalized patients with COVID-19 who have not previously received DOAK by it is not advisable to prescribe POAC for the prevention of thrombosis in patients with COVID-19 due to the lack of clinical trial results, significant potential interactions.
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Izdatelstvo OKI,
2020-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Hospitalized patients with COVID-19 who have not previously received DOAK by it is not advisable to prescribe POAC for the prevention of thrombosis in patients with COVID-19 due to the lack of clinical trial results, significant potential interactions. |
|---|---|
| Item Description: | 2588-0519 2618-8473 10.37489/2588-0519-2020-S4-18-22 |